Certara (CERT)
(Delayed Data from NSDQ)
$11.45 USD
-0.13 (-1.12%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $11.44 -0.01 (-0.09%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.45 USD
-0.13 (-1.12%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $11.44 -0.01 (-0.09%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Zacks News
Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Certara (CERT) delivered earnings and revenue surprises of -36.36% and 1.78%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Certara, Inc. (CERT) Q1 Earnings Meet Estimates
by Zacks Equity Research
Certara (CERT) delivered earnings and revenue surprises of 0% and 2.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Puma Biotechnology (PBYI) Soars 14.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Puma Biotechnology (PBYI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Certara, Inc. (CERT) Lags Q4 Earnings Estimates
by Zacks Equity Research
Certara, Inc. (CERT) delivered earnings and revenue surprises of -18.18% and 1.40%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Certara, Inc. (CERT) Q3 Earnings Meet Estimates
by Zacks Equity Research
Certara, Inc. (CERT) delivered earnings and revenue surprises of 0% and 0.45%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Are Options Traders Betting on a Big Move in Certara (CERT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Certara (CERT) stock based on the movements in the options market lately.
Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 21.43% and 11.08%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Certara, Inc. (CERT) Matches Q1 Earnings Estimates
by Zacks Equity Research
Certara, Inc. (CERT) delivered earnings and revenue surprises of 0% and 1.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Guardant Health (GH) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repligen (RGEN) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of 8.47% and 0.91%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Factors to Note Ahead of Atlassian's (TEAM) Q3 Earnings Release
by Zacks Equity Research
Atlassian's (TEAM) Q3 results are likely to reflect the benefits of increased demand for its solutions amid accelerated digital transformations and cloud adoptions.
DraftKings (DKNG) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
DraftKings' (DKNG) first-quarter 2023 performance is likely to have benefited from the robust demand for mobile sports betting and expansion efforts in new states.
Certara, Inc. (CERT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Certara, Inc. (CERT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights Shake Shack, Wingstop, AssetMark Financial, Primerica and Certara
by Zacks Equity Research
Shake Shack, Wingstop, AssetMark Financial, Primerica and Certara are included in this Analyst Blog.
5 Must-Buy High-Flying Mid-Cap Stocks Ahead of Q1 Earnings
by Nalak Das
We have narrowed our search to five stocks that are set to report first-quarter 2023 earnings results. These are: SHAK, WING, AMK, PRI and CERT.
Creative Medical (CELZ) Up 86% on Upbeat Diabetes Study Data
by Zacks Equity Research
Creative Medical Technology (CELZ) reports positive one-year follow-up data from a study showing the efficacy of CELZ-001 in treating type II diabetes without any serious adverse effects.
Moderna (MRNA) Posts 2027 Biz View, Down 3% on Flu Jab Setback
by Zacks Equity Research
Moderna (MRNA) expects $8-$15 billion in product revenues from the respiratory vaccine by 2027. Its first influenza vaccine candidate failed to meet the statistical threshold for early success.
Moderna (MRNA), Merck's Cancer Jab Gets EMA's PRIME Tag
by Zacks Equity Research
The EMA grants PRIME designation to Moderna's (MRNA) personalized cancer vaccine candidate combined with Merck's Keytruda for treating certain types of melanoma.
MorphoSys Up on Finishing Early Enrolment in Myelofibrosis Study
by Zacks Equity Research
As MorphoSys (MOR) completes enrolment before schedule in a late-stage study evaluating therapy in myelofibrosis patients, the top-line data from this study is now expected early.
AstraZeneca's (AZN) Drug Combo Meets Ovarian Cancer Study Goal
by Zacks Equity Research
Interim data from a late-stage study shows that AstraZeneca's (AZN) cancer drugs, Lynparza and Imfinzi improved progression-free survival in certain patients with advanced ovarian cancer.
VBI Vaccines (VBIV) Down 53% on Initiating Restructuring Plans
by Zacks Equity Research
VBI Vaccines (VBIV) will focus on its HBV vaccine product and advancing its HBV immunotherapeutic candidate. It will also reduce the workforce by 30-35% and initiate a 1-for-30 reverse stock split.
Ascendis (ASND) Down on Hypoparathyroidism Drug NDA Deficiencies
by Zacks Equity Research
The FDA identifies deficiencies in Ascendis' (ASND) regulatory filing for TransCon PTH in hypoparathyroidism. This might lead to an extended review timeline of the company's filing.
Biomea (BMEA) Up 99% on Upbeat Data From Type II Diabetes Study
by Zacks Equity Research
Preliminary data from an ongoing mid-stage study shows that treatment with Biomea's (BMEA) lead candidate demonstrated a robust glucose-lowering response in patients with type II diabetes.
GSK's Jemperli Effective Against First-Line Endometrial Cancer
by Zacks Equity Research
A late-stage study data shows that GSK's Jemperli reduced disease progression risk or death by 72% for treating adult patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Jounce (JNCE) Up 21% on Accepting Concentra's Buyout Offer
by Zacks Equity Research
Jounce Therapeutics (JNCE) is set to be acquired by Concentra Biosciences, spurning an all-share merger deal with British biotech firm Redx Pharma.